Human Insulin (rDNA) from Japan
Recombinant human insulin produced via DNA technology, a polypeptide hormone used primarily for treating diabetes mellitus. Classified under HTS 2937.12.00.00 as a synthetic reproduction of insulin, the exact structural analogue of natural human insulin. Meets chapter 29 requirements for chemically defined organic compounds used as hormones.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Requires FDA approval and biologics license; provide certificates of analysis confirming rDNA origin and purity
• Maintain strict cold chain (2-8°C) documentation throughout transport to preserve bioactivity
• Declare as 'insulin, synthetic' to avoid misclassification with pharmaceutical preparations in Chapter 30